

Healthcare 2023 Preview: Fiscal Cliffs to Drive Congressional Healthcare Policy as Hospitals, Home Health, and Physicians All Face Looming Cuts

January 7, 2023

EXECUTIVE SUMMARY

- Capstone believes Congressional healthcare policy in 2023 will be cliff-driven as lawmakers look to stave off a series of cuts facing providers, hospitals, and home health facilities. In this note, we walk through each fiscal cliff and the resulting impact of action (or inaction).
- The 2022 year-end spending bill will catalyze a wind-down of the temporary 6.2% boost in federal funding for Medicaid programs beginning April 1, 2023, alongside the resumption of Medicaid redeterminations. We estimate Medicaid-focused insurers, namely Centene Corp. (CNC) and Molina Healthcare Inc. (MOH), will see membership reductions of 9.5% and 15.1%, respectively in 2023 and 2024.
- Disproportionate share hospital (DSH) payments, which help offset uncompensated care costs, will be slashed by \$32 billion over four years without congressional action before October 31, 2023. The cuts have been repeatedly delayed since their enactment via the Affordable Care Act (ACA). Capstone believes this trend will continue, with Congress stepping in to appease the hospital lobby and dependent states.
- Congress is boosting physician fee schedule (PFS) payments by 2.5% in 2023 and 1.25% in 2024. The reduction in relief in 2024 will feel like a 1.25 percentage point cut to physicians, worsened by the arrival of a new G-code that will place an additional 3% cut on physician rates. Physician advocacy groups will need to work with the new Congress in 2023 to avert an overall reduction in 2024 and establish a permanent PFS solution.
- Home health providers are facing two types of cuts in the coming years: a 3.5% market basket reduction in 2024 in response to Patient-driven Groupings Model (PDGM) cuts and \$2.1B in outstanding clawbacks due to Centers for Medicare & Medicaid Services (CMS) calculated overspending in 2020 and 2021. CMS has not released a timeline or updated projection for the clawbacks, which are expected to grow significantly to account for overspending in 2022 and 2023. Home health lobbyists will likely seek to have Congress remove the clawback requirement entirely.
- Round 2021 of the durable medical equipment (DME) competitive bidding program will end in 2023, setting the stage for new product categories to be introduced in 2024. In 2021, most product categories were scrapped from the program due to the pandemic and a lack of savings for CMS. Capstone believes CMS will look to bring back a wider selection of categories in the upcoming Round 2024, potentially including ventilators.
- After winning a third consecutive delay to fee schedule cuts mandated by the Protecting Access to Medicare Act (PAMA), clinical labs are unlikely to continue avoiding Medicare payment cuts in 2024.

A DEEPER LOOK

Major Themes in 2022

Medicaid Redeterminations to Begin April 1, 2023


Winners and Losers from Medicaid Redeterminations	
Winners	Elevance Health Inc. (ELV), UnitedHealth Group Inc. (UNH), Cigna Corp. (CI)
Losers	Molina Healthcare Inc. (MOH), Centene Corp. (CNC)

The 2023 congressional [year-end spending bill](#) requires that states begin Medicaid redeterminations starting April 1, 2023. The pause on Medicaid redeterminations has been in effect since the passage of the [Families First Coronavirus Response Act](#) in March 2020. The legislation increased federal funding for Medicaid’s Federal Medical Assistance Percentage (FMAP) by 6.2% in exchange for states agreeing not to conduct eligibility checks and therefore not to kick any individual off of Medicaid. The pause on redeterminations has led to significant growth in the Medicaid program—Capstone projects total enrollment growth of 31% (over 20 million individuals) by March 2023 from March 2020.

The redetermination process is therefore expected to spur significant disenrollment. Democrats were unable to secure guardrails on the process that were included in the proposed [Build Back Better](#) redetermination, including limiting the number of people per month states could disenroll. However, Congress will attempt to control the disenrollment process by phasing down the enhanced FMAP through the end of 2023. The enhanced match will decrease to 5% on April 1st, 2.5% on July 1st, 1.5% on October 1st, and 0% on December 31, 2023.

With massive disenrollment, major Medicaid managed care insurers Molina and Centene will experience significant decreases in covered lives, with Molina set to lose an estimated [\\$467 million](#) in annual gross profit. Molina will experience further membership losses following the [announcement](#) that Centene has been issued new California Medicaid contracts beginning January 1, 2024. Large Affordable Care Act (ACA) Marketplace insurers Cigna, Elevance, and UnitedHealth are likely to see a neutral-to-positive impact of disenrolled Medicaid beneficiaries switching to an ACA plan (see: [Healthcare Weekly: Congress Looks to Decouple Medicaid Redeterminations From PHE, Slashing Molina, Centene’s Membership by 15.1% and 9.5%](#), December 10, 2022).

Exhibit 1: Insurer Net Membership Change in Lives, Base/Best/Worst Case



Source: Capstone analysis

Note: Our base case uses a Medicaid redetermination disenrollment percentage of 17.3%, as estimated by the Urban Institute. Based on previously released data suggesting higher disenrollment, our worst-case scenario uses a disenrollment percentage of 20%. Our base case scenario uses a disenrollment percentage of 15%.

DSH Cuts to Come in October 2023 Without Congressional Intervention

Winners and Losers from DSH Payment Cuts	
Winners	None
Losers	Tenet Healthcare Corp. (THC), HCA Healthcare Inc. (HCA), Community Health Systems Inc. (CYH), Universal Health Services Inc. (UHS)

Disproportionate Share Hospital (DSH) payments are federal payments to hospitals that serve a large number of Medicaid and uninsured patients. The ACA included a reduction in DSH payments of \$18 billion beginning in 2014. The cuts were intended to incentivize states to expand Medicaid and invest in other reforms that would reduce the number of uninsured individuals. If the cuts proceed and states feel increased pressure to expand Medicaid to decrease uncompensated care costs, major Medicaid managed care organizations (MCOs) will see some benefits from increased enrollment. However, following hospital industry lobbying pushes, the cuts have not yet taken effect, having been delayed several times by Congress.

Most recently, the [2021 year-end spending bill](#) delayed the cuts until October 31, 2023. If they proceed, \$8 billion would be cut in each fiscal year from 2024 to 2027, totaling \$32 billion. The cuts would slash federal 2022 DSH contributions by 59.7% and total federal and state DSH contributions by 34%. In addition to DSH payments, seven states, including Florida, Texas, and Tennessee (large non-expansion states), have uncompensated care (UCC) waivers that further

supplement the amount of money hospitals receive for uncompensated care. The Biden administration has yet to pare back these waiver approvals and more states could seek similar approvals if DSH payments remain in jeopardy.


During 2021 Build Back Better (BBB) negotiations, Democrats tried to add DSH cuts for non-expansion states to the looming ACA cuts by reducing DSH allotments by 12.5% and limiting Medicaid UCC pool funding in non-expansion states. These policies would have been supplemented by a temporary FMAP increase to 93% for states that expanded Medicaid and subsidies to people in the coverage gap in non-expansion states. However, even with Congressional Budget Office (CBO) estimates of an \$18 billion reduction in spending over five years (2022-2026) and a \$35 billion reduction over 10 years (2022-2031), the proposal ultimately did not make it into the US Senate Committee on Finance’s [published version of BBB](#) or the final [Inflation Reduction Act \(IRA\)](#), largely due to [hospital industry pushback](#). Even with Democratic disagreement on DSH allotments, Capstone ultimately believes that the cuts will be delayed again to prevent extreme decreases in safety net hospital funding, providing a vehicle for other Medicaid reform within Congress.

Exhibit 2: DSH Payments in 2021 (in millions)

Hospital System	DSH Payments, 2021	Estimated DSH Cuts Using 2021 Values	Cuts as a % of 2021 Operating Income
THC	\$174	\$107	6.1%
UHS	\$51	\$31	2.3%
CYH	\$67	\$41	2.9%

Source: Capstone analysis, hospital system financials
Capstone assumes that the DSH cuts would be equal across all hospital systems

Exhibit 3: Federal and State DSH Allotments Since 2016 (in billions)



Source: MACPAC Annual Analysis of Disproportionate Share Hospital Allotments to States


Medicare Physician Fee Schedule in Need of Congressional Revamp

Winners and Losers from Physician Fee Schedule Cuts	
Winners	Medicare Advantage insurers, including Elevance Health Inc. (ELV), UnitedHealth Group Inc. (UNH), Humana Inc. (HUM)
Losers	Envision Healthcare Corp. (EVHC), TeamHealth Holdings Inc. (TMH), Pediatrix Medical Group Inc. (MD), US Anesthesia Partners Inc., Akumin Inc. (AKU), RadNet Inc. (RDNT), SimonMed Imaging, Radiology Partners

Conversion factor reductions that began in 2021 from boosts to primary care codes continue to place pressure on fee schedule budget neutrality. Congressional mitigation has provided some relief, though a G-code delayed since 2021 combined with the roll-off of 2023 relief will create a new cliff in 2024. By acting on the 2024 fee schedule early, Congress has signaled to physicians the ball is in their court to propose a new permanent solution as we near the 10-year anniversary of the Medicare Access and CHIP Reauthorization Act of 2015. The American Medical Association (AMA) will be one of many physician groups working with the new Congress on a solution—including the potential for rates to be frozen at current levels and/or the introduction of an inflationary update. A permanent solution to the PFS system may modestly benefit Medicare Advantage insurers, who otherwise get hit by last minute changes to Medicare rates. Outside of budget neutrality pressure, physician specialties such as radiology will continue to be cut incrementally by the phase-in for clinical labor repricing through 2025.

Congress delayed statutory pay-as-you-go (PAYGO) cuts from 2023 to 2025 in the end-of-year spending bill. This will set up the same fight towards the end of 2024 to continue to avoid a 4% reduction across Medicare payment systems. Continuing to waive PAYGO will cost increasingly more, forcing Congress to either continue delaying it, to find more than \$30 billion to pay for a waiver, or to let the cuts take effect in 2025.

Exhibit 4: Physician Fee Schedule Conversion Factor Trends and 2024 Expected Cuts



Home Health Providers Face Two Forms of Cuts Without Congressional Action

Winners and Losers from Home Health Cuts	
Winners	None
Losers	Amedisys Inc. (AMED), Enhabit Inc. (EHAB), LHC Group Inc. (LHCG), Humana Inc. (HUM), Elara Caring

After failing to win a delay in cuts in the 2022 spending bill, home health companies face a 3.5% reduction to their market baskets in both 2023 and 2024. With 2023 resulting in a 0.7% net gain to Medicare rates, the 2024 update is likely to be very similar unless a large swing in inflation moves projections. A potentially larger threat to home health will be temporary clawbacks beginning as early as 2024. Overspending estimates between 2020 and 2021 would necessitate a ~12% cut, which could double after the inclusion of 2022 and 2023 estimates. CMS has not proposed a timeline for these clawbacks, but is required by law to complete them by 2026. It has cautioned in rulemaking that action by providers to reduce visits per patient to offset costs would result in greater reductions in the future, creating a downward spiral for Medicare reimbursement.

If CMS were to phase in a clawback of 20% between 2024 and 2026, the resulting impact would be a net negative of approximately 7% in 2024 (assuming a 3.5% market basket and 3.5% PDGM permanent cut), followed by market basket updates in 2025 and 2026. In 2027, the market basket update would be boosted by the return of the 6.7% temporary setback. Since all clawbacks will be temporary, each year's expiring cut will be added to the following year's boost after the first cut. In CMS's eyes, the lagging 6.7% below benchmark for each year creates savings for the program that would satisfy the clawback requirement. Home health agencies and lobbying organizations are expected to begin lobbying efforts to avoid these cuts as early as this year.

DME Competitive Bidding to Return in 2024, Many Categories Have Been Excluded Since 2018

Winners and Losers from Durable Medical Equipment Competitive Bidding	
Winners	None
Losers	AdaptHealth Corp. (AHCO), Owens & Minor Inc. (OMI)

Following a gap between 2019 and 2020, competitive bidding for DME resumed in 2021 for only a portion of the original product categories due to COVID-19 disruptions. After not finding savings for most product categories, CMS removed ventilators, oxygen, and others from the process and only moved forward with off-the-shelf knee and orthotic braces. CMS is required by law to recomplete the program at least every three years, indicating Round 2024 bidding will begin sometime in mid-to-late 2023.

The risk of payment reductions will be highest for product categories which have not previously been included in competitive bidding, such as non-invasive ventilators. Once included in competitive bidding, [research](#) has shown product prices drop by 45% on average. Pricing drops vary significantly by medical savings account (MSA) and have been shown to stabilize after an initial cliff. That said, the five-year gap for most product categories since the last round of competitive bidding suggests a market shake-up if competitive bidding is not further delayed.

PAMA Clinical Laboratory Reductions Scheduled to Resume in 2024, Capped at 15% Until 2026

Winners and Losers from the Resumption of PAMA Clinical Lab Cuts	
Winners	None
Losers	Quest Diagnostics Inc. (DGX), Laboratory Corp. of America Holdings (LH)

The Protecting Access to Medicare Act of 2014 (PAMA) lined up a series of cuts for Medicare clinical laboratory payments over the following decade. From 2018-2020, Medicare fee schedule rates for clinical laboratory services began to be adjusted to match commercial median rates. Any reductions to services were capped at 10% each year. Payment reduction caps were set to increase to 15% for the 2021-2023 period before the Coronavirus Aid, Relief, and Economic Security (CARES) Act instituted the first delay to subsequent cuts. These cuts were delayed to 2024 through legislation in late 2021 and 2022.

Now, with COVID-19 receding, clinical laboratories are likely to see cuts resume. The impact of continued repricing will vary significantly by service, as previously, some services only felt cuts for one-to-two years of the phase-in while limited services received increases. However, for many services on the clinical lab fee schedule, reductions of up to 15% for the next three years present a significant overhang in the absence of additional congressional delay.

In Case You Missed It: A roundup of Capstone’s recent notes on healthcare:

[Mental Health 2023 Preview: Providers to Win on the Back of Recent Legislative and Regulatory Reform, Sharper Parity Efforts to Come](#), December 30, 2022

[Healthcare Weekly: Medicare Advantage Proposed Rule to Squeeze Plans Beginning in 2027 Due to \\$25B in Star Ratings Cuts and Increased Spending](#), December 17, 2022

[Healthcare Weekly: Congress Looks to Decouple Medicaid Redeterminations From PHE, Slashing Molina, Centene’s Membership by 15.1% and 9.5%](#), December 10, 2022

[Healthcare Weekly: Further Bipartisan Healthcare Legislation Likely in End of Year Spending Bill, a Harbinger of More Meaningful Action to Come](#), December 3, 2022

What We’re Reading:

[Manufacturers May Need Additional Guidance To Ensure Consistent Calculations of Average Sales Prices](#), HHS Office of Inspector General

[Physician Group Practices Struggle with Bundled Payments: Study](#), Fierce Healthcare

[‘Not Business as Usual’: Health Lobbyists Brace for Bernie Sanders](#), Politico

[A Tough Year for Insurtechs Raises Questions About the Future](#), Modern Healthcare

[Federal IDR Process Faces More Disputes Than Expected, Backlog Growing](#), Revcycle Intelligence

[Medical Bills Heading to Dispute Resolution Far More Often than Anticipated](#), Axios

[Medicare Lost Millions in Savings Due to Spotty Oversight: Federal Watchdog](#), The Hill

[Pfizer, GSK, AbbVie and Many More Celebrate New Year with Price Hikes: Report](#), Fierce Pharma

Look Ahead Calendar:

Health Affairs Event on National Health Care Spending In 2021: Decline in Federal Spending Outweighs Greater Use Of Health Care

- January 10, 2023 at 1:00 p.m. EST
- To register, click [here](#)
- For more information, contact [Max Reale](#)

NASHP Event on Strategies for State-Local Collaboration in Opioid Settlement Spending: Spotlight on Nevada and Wisconsin

- January 11, 2023 at 12:00 p.m. EST
- To register, click [here](#)
- For more information, contact [Max Reale](#)

MedPAC January Public Meeting

- January 12-13
- To register, click [here](#)
- For more information, contact [Grace Totman](#)

MACPAC January Public Meeting

- January 26-27
- To register, click [here](#)
- For more information, contact [Grace Totman](#)

MA/RADV Call Letter

- Expected January
- For more information, contact [Grace Totman](#)

States Required to Begin Medicaid Redetermination

- April 1, 2023
- For more information, contact [Grace Totman](#)

Presumed End of the Public Health Emergency (PHE)

- April 11, 2023
- For more information, contact [Grace Totman](#)

Capstone J.P. Morgan Healthcare Conference Reception

Wednesday, January 11, 2023, from 10:30 a.m. – 1:00 p.m. PST

Please join Capstone’s healthcare team in San Francisco for a reception to discuss the 2023 outlook for pertinent healthcare issues including value-based care, Medicare Advantage, behavioral health, provider reimbursement, and more.

You are welcome to stay for the entire time or stop by for a short while—food and beverages will be provided.

If you are interested in attending, please contact your Capstone sales representative or RSVP@capstonedc.com.

Opportunities to Connect

Let us know if you would like to schedule a time to meet during one of our upcoming marketing trips. Contact sales@capstonedc.com to schedule. Dates are subject to change.

San Francisco, CA: January 9-12, 2023